Literature DB >> 10953055

Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1.

A Piiper1, R Gebhardt, B Kronenberger, C D Giannini, R Elez, S Zeuzem.   

Abstract

Pertussis toxin (PTx), which inactivates G(i/o) type G proteins, is widely used to investigate the involvement of G(i/o) proteins in signal transduction. Activation of extracellular-regulated kinases 1 and 2 (ERK1/2) by G protein-coupled receptors has been described to occur either through a PTx-insensitive pathway involving activation of phospholipase C and protein kinase C (PKC), or through a PTx-sensitive pathway involving G(i)betagamma-mediated activation of Src. Cholecystokinin (CCK) activates ERK1/2 by a PKC-dependent, and thus presumably PTx-insensitive, pathway. However, CCK has recently been shown to induce activation of G(i) proteins in addition to G(q/11). In the present study, PTx partially inhibited CCK-induced ERK1/2 activation in pancreatic AR42J cells, although activation of phospholipase C was not reduced. PTx also inhibited ERK1/2 activation in response to the PKC activator 12-O-tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor (EGF) as well as activation of c-Raf-1 by EGF and CCK. In contrast, PTx, CCK, and EGF had only minor effects on A-Raf and B-Raf activity. Forskolin, a direct activator of adenylyl cyclase, inhibited CCK- and EGF-induced activation of c-Raf-1 and ERK1/2 in a manner similar to that of PTx. In PTx-treated cells, the cAMP content was increased and forskolin did not further inhibit CCK- and EGF-induced activation of c-Raf-1 or ERK1/2. In conclusion, the present study shows that PTx-sensitivity of receptor-induced ERK1/2 activation could be a consequence of disinhibition of the adenylyl cyclase signaling pathway, which in turn causes inhibition of c-Raf-1 activation rather than indicating involvement of a PTx-sensitive G protein in this signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953055     DOI: 10.1124/mol.58.3.608

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.

Authors:  Niannian Ji; Nagarjun Rao; Neal M Guentzel; Bernard P Arulanandam; Thomas G Forsthuber
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells.

Authors:  Simone Kiermayer; Ricardo M Biondi; Jochen Imig; Guido Plotz; Jörg Haupenthal; Stefan Zeuzem; Albrecht Piiper
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

3.  CAP37 activation of PKC promotes human corneal epithelial cell chemotaxis.

Authors:  Gina L Griffith; Robert A Russell; Anne Kasus-Jacobi; Elangovan Thavathiru; Melva L Gonzalez; Sreemathi Logan; H Anne Pereira
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-15       Impact factor: 4.799

4.  Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

Authors:  M Mata; B Sarriá; A Buenestado; J Cortijo; M Cerdá; E J Morcillo
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

5.  Calcium signaling cascades differentially regulate PGF-induced myometrial contractions in water buffaloes (Bubalus bubalis).

Authors:  Abhishek Sharma; Udayraj P Nakade; Raut Akash; Virendra Pratap Yadav; Soumen Choudhury; Pooja Jaitley; Vipin Sharma; Satish Kumar Garg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-04-22       Impact factor: 3.000

6.  Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.

Authors:  Kheng Tian Lim; Niamh Cosgrave; Arnold David Hill; Leonie S Young
Journal:  Breast Cancer Res       Date:  2006-06-28       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.